Citations

Clear

4610 citation(s) found for "Lu, Brian".

Improvement in Diagnosis and Management of Nosocomial Pneumonias in a Cardiovascular Surgery Intensive Care Unit: A Multidisciplinary Approach
Kooda, Kirstin , Zambrano, Alejandra A. , Kosaski, Dylan L. , Higbe, Leah, Beam, William B. , Bohman, J. Kyle , Wittwer, Erica D. , Brady, Steven D., LeMahieu, Allison , Shah, Aditya , Kooda, Kirstin J, Beam, William Brian B, Bohman, John K , LeMahieu, Allison M , Kosaski, Dylan , Fida, Madiha

Mayo Clinic

Antibiotics | June 26, 2024 | Volume: 13 | Issue: 7 | Pages: 590

10.3390/antibiotics13070590 | PMID 39061272 Get It

Background: While criteria for the diagnosis of nosocomial pneumonias exist, objective definitions are a challenge and there is no gold standard for diagnosis. We analyzed the impact of the implementation of a logical, consensus-based diagnostic and treatment protocol for managing nosocomial pneumonias in the cardiovascular surgery intensive care unit (CVS-ICU). Methods: We conducted a quasi-experimental, interrupted time series analysis to evaluate the impact of a diagnostic and treatment protocol for nosocomial pneumonias in the CVS-ICU. Impacts were measured relative to patient outcomes, diagnostic processes, and antimicrobial stewardship improvement. Descriptive statistics were used to analyze results. Results: Overall, 35 pre-protocol and 39 post-protocol patients were included. Primary clinical variables suggesting pneumonia in pre- and post-protocol patients were new lung consolidation (50% vs. 71%), new leukocytosis (59% vs. 64%), and positive culture (32% vs. 55%). Appropriate diagnostic testing improved (23% vs. 54%, p = 0.008) after protocol implementation. The proportion of patients meeting the criteria for nosocomial pneumonia (77% vs. 87%) was not statistically significant, though more patients in the post-protocol group met probable diagnostic criteria (51% vs. 77%). Duration of therapy was not significantly different (6 days [IQR = 5.0, 10.0] vs. 7 days [IQR = 6.0, 9.0]). Conclusions: The implementation of a diagnostic and treatment protocol for management of nosocomial pneumonias in the CVS-ICU resulted in improved diagnostic accuracy, advanced antimicrobial and diagnostic stewardship efforts, and laboratory cost savings without an adverse impact on patient-centered outcomes.
Provider‐to‐provider telemedicine for sepsis is used less frequently in communities with high social vulnerability
Tu, Kevin J. , Vakkalanka, J. Priyanka , Okoro, Uche E., Harland, Karisa K. , Wymore, Cole, Campbell, Kalyn, Swanson, Morgan B. , Parker, Edith A. , Mack, Luke , DeJong, Katie, Faine, Brett , Zepeski, Anne , Mueller, Keith J. , Jones, Michael P. , Mohr, Nicholas M. , Swanson, Morgan B , Mueller, Keith , Mohr, Nicholas M , Faine, Brett A , Vakkalanka, Priyanka , Fuller, Brian M. , Bell, Amanda L. , Chrischilles, Elizabeth A. , Carpenter, Christopher R. , Ward, Marcia M.

Mayo Clinic

The Journal of Rural Health | June 26, 2024 | Volume: 41 | Issue: 1 | Pages: No page available

10.1111/jrh.12861 | PMID 38924559 Get It

Abstract Purpose Sepsis disproportionately affects patients in rural and socially vulnerable communities. A promising strategy to address this disparity is provider‐to‐provider emergency department (ED)‐based telehealth consultation (tele‐ED). The objective of this study was to determine if county‐level social vulnerability index (SVI) was associated with tele‐ED use for sepsis and, if so, which SVI elements were most strongly associated. Methods We used data from the TELEmedicine as a Virtual Intervention for Sepsis in Rural Emergency Department study. The primary exposures were SVI aggregate and component scores. We used multivariable generalized estimating equations to model the association between SVI and tele‐ED use. Findings Our study cohort included 1191 patients treated in 23 Midwestern rural EDs between August 2016 and June 2019, of whom 326 (27.4%) were treated with tele‐ED. Providers in counties with a high SVI were less likely to use tele‐ED (adjusted odds ratio [aOR] = 0.51, 95% confidence interval [CI] 0.31‒0.87), an effect principally attributable to the housing type and transportation component of SVI (aOR = 0.44, 95% CI 0.22–0.89). Providers who treated fewer sepsis patients (1‒10 vs. 31+ over study period) and therefore may have been less experienced in sepsis care, were more likely to activate tele‐ED (aOR = 3.91, 95% CI 2.08‒7.38). Conclusions Tele‐ED use for sepsis was lower in socially vulnerable counties and higher among providers who treated fewer sepsis patients. These findings suggest that while tele‐ED increases access to specialized care, it may not completely ameliorate sepsis disparities due to its less frequent use in socially vulnerable communities.
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
Patel‐Murray, Natasha , Zhang, Luqing , Claggett, Brian , Xu, Dongchu , Serrano‐Fernández, Pablo , Healey, Margaret L. , Wandel, Simon , Jacob, Jaison , Xu, Huilei , Chutkow, William A., O’Donnell, Christopher J. , Prescott, Margaret F., Lefkowitz, Marty , Gimpelewicz, Claudio , Zhao, Faye, Gou, Liangke , Redfield, Margaret M. , Rouleau, Jean L. , Zannad, Faı̈ez , Solomon, Scott D. , Patel-Murray, Natasha L , Claggett, Brian L , Healey, Margaret , Jacob, Jaison , Xu, Huilei , Turner, Gordon M , Yates, Denise P , O'Donnell, Christopher J , Lefkowitz, Martin P , Gimpelewicz, Claudio R , Beste, Michael T , Gou, Liangke , Desai, Akshay S , Jhund, Pardeep S , Packer, Milton , Pfeffer, Marc Alan , Redfield, Margaret M , Rouleau, Jean L , Zannad, Faiez , Zile, Michael R , McMurray, John J V , Mendelson, Michael M , Solomon, Scott David , Cunningham, Jonathan W , Chen, Chien‐Wei , Jhund, Pardeep S. , Packer, Milton , Zile, Michael R. , McMurray, John J.V. , Cunningham, Jonathan W.

Mayo Clinic

Journal of the American Heart Association | June 21, 2024 | Volume: 13 | Issue: 13 | Pages: No page available

10.1161/jaha.123.033544 | PMID 38904251 Get It

Background Prognostic markers and biological pathways linked to detrimental clinical outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely defined. Methods and Results We measured serum levels of 4123 unique proteins in 1117 patients with HFpEF enrolled in the PARAGON‐HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) trial using a modified aptamer proteomic assay. Baseline circulating protein concentrations significantly associated with the primary end point and the timing and occurrence of total heart failure hospitalization and cardiovascular death were identified by recurrent events regression, accounting for multiple testing, adjusted for age, sex, treatment, and anticoagulant use, and compared with published analyses in 2515 patients with heart failure with reduced ejection fraction from the PARADIGM‐HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and ATMOSPHERE (Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity–Mortality in Patients With Chronic Heart Failure) clinical trials. We identified 288 proteins that were robustly associated with the risk of heart failure hospitalization and cardiovascular death in patients with HFpEF. The baseline proteins most strongly related to outcomes included B2M (β‐2 microglobulin), TIMP1 (tissue inhibitor of matrix metalloproteinase 1), SERPINA4 (serpin family A member 4), and SVEP1 (sushi, von Willebrand factor type A, EGF, and pentraxin domain containing 1). Overall, the protein–outcome associations in patients with HFpEF did not markedly differ as compared with patients with heart failure with reduced ejection fraction. A proteomic risk score derived in patients with HFpEF was not superior to a previous proteomic score derived in heart failure with reduced ejection fraction nor to clinical risk factors, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), or high‐sensitivity cardiac troponin. Conclusions Numerous serum proteins linked to metabolic, coagulation, and extracellular matrix regulatory pathways were associated with worse HFpEF prognosis in the PARAGON‐HF proteomic substudy. Our results demonstrate substantial similarities among serum proteomic risk markers for heart failure hospitalization and cardiovascular death when comparing clinical trial participants with heart failure across the ejection fraction spectrum. Registration URL: https://www.clinicaltrials.gov ; Unique Identifiers: NCT01920711, NCT01035255, NCT00853658.
Current opinion: functional dyspepsia
Olson, Caroline G. , Travers, Paul , Lacy, Brian E. , Olson, Caroline , Travers, Paul

Mayo Clinic

Current Opinion in Gastroenterology | June 20, 2024 | Volume: 40 | Issue: 6 | Pages: 470-476

10.1097/mog.0000000000001045 | PMID 39360697 Get It

Purpose of review Functional dyspepsia is a common gastrointestinal disease that is under-recognized and under-diagnosed. It is a complex disorder of gut–brain interaction with no FDA-approved treatment options. The purpose of this review is to highlight updates in the proposed pathophysiology and present new data regarding potential therapies for functional dyspepsia. Recent findings Alterations in the intestinal microbiome and integrity of the intestinal membrane may play a crucial role in the pathogenesis of functional dyspepsia. The low FODMAP diet, in addition to modulating the microbiome with antibiotics and probiotics, are targets for large future studies. Novel methods of delivery of gut–brain therapies have shown promising results, especially virtual reality. Summary The pathophysiology and management of functional dyspepsia is complex and there is still much unknown; however, continued research is identifying new targets for treatment. New and more targeted treatment options provide clinicians a variety of tools to offer patients with functional dyspepsia.
Endoscopic scoring indices for assessing disease severity in familial adenomatous polyposis: Systematic review
Silverman, Anna L. , Bouchiba, Hicham , Aelvoet, Arthur S. , MacDonald, John K, Dekker, Evelien , Zayadi, Alexa, Le, Jessica, Feagan, Brian G. , Jairath, Vipul , Ma, Christopher , Samadder, Jewel, Jairath, Vipul , Jairath, Vipul , Silverman, Anna Lerman , Jairath, V , Jairath, V , Dekker, Evelien , Jairath, Vipul , Le, Jessica

Mayo Clinic

Endoscopy International Open | June 18, 2024 | Volume: 12 | Issue: 06 | Pages: E799-E809

10.1055/a-2330-8037 | PMID 38904059 Get It

Abstract Background and study aims There is limited consensus on the optimal method for measuring disease severity in familial adenomatous polyposis (FAP). We aimed to systematically review the operating properties of existing endoscopic severity indices for FAP. Methods We searched MEDLINE, EMBASE, and the Cochrane Library from inception to February 2023 to identify randomized controlled trials (RCTs) that utilized endoscopic outcomes or studies that evaluated the operating properties of endoscopic disease severity indices in FAP. Results A total of 134 studies were included. We evaluated scoring indices and component items of scoring indices, such as polyp count, polyp size, and histology. Partial validation was observed for polyp count and size. The most commonly reported scoring index was the Spigelman classification system, which was used for assessing the severity of duodenal involvement. A single study reported almost perfect interobserver and intra-observer agreement for this system. The InSIGHT polyposis staging system, which was used for assessing colorectal polyp burden, has been partially validated. It showed substantial interobserver reliability; however, the intra-observer reliability was not assessed. Novel criteria for high-risk gastric polyps have been developed and assessed for interobserver reliability. However, these criteria showed a poor level of agreement. Other scoring indices assessing the anal transition zone, duodenal, and colorectal polyps have not undergone validation. Conclusions There are no fully validated endoscopic disease severity indices for FAP. Development and validation of a reliable and responsive endoscopic disease severity instrument will be informative for clinical care and RCTs of pharmacological therapies for FAP.
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
Etra, Aaron , Jurdi, Najla El , Katsivelos, Nikolaos , Gergoudis, Stephanie, Morales, George , Spyrou, Nikolaos , Kowalyk, Steven, Aguayo‐Hiraldo, Paibel , Akahoshi, Yu , Ayuk, Francis, Baez, Janna , Chanswangphuwana, Chantiya , Chen, Yi‐Bin , Choe, Hannah , DeFilipp, Zachariah , Gleich, Sigrun, Holler, Ernst , MacMillan, Margaret L. , Pawarode, Attaphol , Quagliarella, Francesco , Schechter, Tal , Vášová, Ingrid, Wölfl, Matthias , Young, Rachel , Nakamura, Ryotaro , Ferrara, James L.M. , El Jurdi, Najla , Spyrou, Nikolaos , Aguayo-Hiraldo, Paibel , Chen, Yi-Bin , DeFilipp, Zachariah , Hexner, Elizabeth , Hogan, William J , Al Malki, Monzr M , Quagliarella, Francesco , Qayed, Muna , Weisdorf, Dan , Wölfl, Matthias , Nakamura, Ryotaro , Levine, John E , Holtan, Shernan , Katsivelos, Nikolaos , Akahoshi, Yu , Kwon, Deukwoo , Betts, Brian Christopher , Hexner, Elizabeth O. , Hogan, William J. , Kitko, Carrie L. , Kraus, Sabrina , Malki, Monzr M. Al , Reshef, Ran , Weisdorf, Daniel J. , Levine, John E. , Holtan, Shernan G.

Mayo Clinic

Blood Advances | June 14, 2024 | Volume: 8 | Issue: 12 | Pages: 3284-3292

10.1182/bloodadvances.2023011049 | PMID 38640195 Get It

Abstract Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination of 2 GI GVHD biomarkers (suppressor of tumorigenicity-2 [ST2] + regenerating family member 3 alpha [REG3α]) when measured at GVHD diagnosis are validated predictors of NRM risk but have never been assessed in the same patients using identical statistical methods. We measured the serum concentrations of ST2, REG3α, and AREG by enzyme-linked immunosorbent assay at the time of GVHD diagnosis in 715 patients divided by the date of transplantation into training (2004-2015) and validation (2015-2017) cohorts. The training cohort (n = 341) was used to develop algorithms for predicting the probability of 12-month NRM that contained all possible combinations of 1 to 3 biomarkers and a threshold corresponding to the concordance probability was used to stratify patients for the risk of NRM. Algorithms were compared with each other based on several metrics, including the area under the receiver operating characteristics curve, proportion of patients correctly classified, sensitivity, and specificity using only the validation cohort (n = 374). All algorithms were strong discriminators of 12-month NRM, whether or not patients were systemically treated (n = 321). An algorithm containing only ST2 + REG3α had the highest area under the receiver operating characteristics curve (0.757), correctly classified the most patients (75%), and more accurately risk-stratified those who developed Minnesota standard-risk GVHD and for patients who received posttransplant cyclophosphamide-based prophylaxis. An algorithm containing only AREG more accurately risk-stratified patients with Minnesota high-risk GVHD. Combining ST2, REG3α, and AREG into a single algorithm did not improve performance.
Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk
Ni, Zhanmo , Kundu, Prosenjit , McKean, David , Wheeler, William , Albanes, Demetrius , Andreotti, Gabriella , Antwi, Samuel O. , Arslan, Alan A. , Bamlet, William R. , Freeman, Laura E. Beane , Berndt, Sonja I. , Bracci, Paige M. , Brennan, Paul , Buring, Julie E. , Gallinger, Steven , Gaziano, J. Michael , Giovannucci, Edward L. , Goodman, Phyllis J. , Haiman, Christopher A. , Hassan, Manal M. , Holly, Elizabeth A. , Li, Donghui , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Visvanathan, Kala , White, Emily , Wolpin, Brian M. , Zhong, Jun, McKean, David F , Beane Freeman, Laura E , Chanock, Stephen Jacob , Gallinger, Steven , Gaziano, J Michael , Giles, Graham G , Giovannucci, Edward L , Goggins, Michael G , Goodman, Phyllis J , Haiman, Christopher A , Hassan, Manal M , Holly, Elizabeth A , Hung, Rayjean J , Katzke, Verena , Kooperberg, Charles , Kraft, Peter , Marchand, Loïc Le , Li, Donghui , McCullough, Marjorie L , Milne, Roger L , Moore, Steven C , Neale, Rachel E , Oberg, Ann L , Patel, Alpa V , Peters, Ulrike , Chaffee, Kari G. , Risch, Harvey A , Shu, Xiao-Ou , Smith-Byrne, Karl , Visvanathan, Kala , Wactawski-Wende, Jean , White, Emily , Wolpin, Brian M , Yu, Herbert , Zeleniuch-Jacquotte, Anne , Zheng, Wei , Zhong, Jun , Amundadottir, Laufey , Stolzenberg-Solomon, Rachael , Klein, Alison P , Antwi, Samuel O , Arslan, Alan A , Bamlet, William R , Albanes, Demetrius , Giles, Graham G. , Goggins, Michael , Hung, Rayjean J. , Kooperberg, Charles , Kraft, Peter , Marchand, Loı̈c Le , McCullough, Marjorie L. , Milne, Roger L. , Moore, Steven C. , Neale, Rachel Ε. , Rabe, Kari G. , Risch, Harvey A. , Shu, Xiao‐Ou , Wactawski‐Wende, Jean , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Zheng, Wei , Ámundadóttir, Laufey T. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 13, 2024 | Volume: 33 | Issue: 9 | Pages: 1229-1239

10.1158/1055-9965.epi-24-0096 | PMID 38869494 Get It

Abstract Background: Pancreatic cancer is a leading cause of cancer-related death globally. Risk factors for pancreatic cancer include common genetic variants and potentially heavy alcohol consumption. We assessed if genetic variants modify the association between heavy alcohol consumption and pancreatic cancer risk. Methods: We conducted a genome-wide interaction analysis of single-nucleotide polymorphisms (SNP) by heavy alcohol consumption (more than three drinks per day) for pancreatic cancer in European ancestry populations from genome-wide association studies. Our analysis included 3,707 cases and 4,167 controls from case–control studies and 1,098 cases and 1,162 controls from cohort studies. Fixed-effect meta-analyses were conducted. Results: A potential novel region of association on 10p11.22, lead SNP rs7898449 (interaction P value (Pinteraction) = 5.1 × 10−8 in the meta-analysis; Pinteraction = 2.1 × 10−9 in the case–control studies; Pinteraction = 0.91 in the cohort studies), was identified. An SNP correlated with this lead SNP is an expression quantitative trait locus for the neuropilin 1 gene. Of the 17 genomic regions with genome-wide significant evidence of association with pancreatic cancer in prior studies, we observed suggestive evidence that heavy alcohol consumption modified the association for one SNP near LINC00673, rs11655237 on 17q25.1 (Pinteraction = 0.004). Conclusions: We identified a novel genomic region that may be associated with pancreatic cancer risk in conjunction with heavy alcohol consumption located near an expression quantitative trait locus for neuropilin 1, a protein that plays an important role in the development and progression of pancreatic cancer. Impact: This work can provide insights into the etiology of pancreatic cancer, particularly in heavy drinkers.
Proactive, automated monitoring of uncontrolled symptoms in prostate cancer survivors across the cancer control continuum.
Muniz, Miguel, Ruddy, Kathryn J. , Grzegorczyk, Veronica , Pachman, Deirdre R. , Cobran, Ewan K. , Loprinzi, Charles L. , Costello, Brian A. , Orme, Jacob J. , Childs, Daniel S. , Morgans, Alicia K. , Griffin, Joan M. , Smith, Ashley Wilder , Kroenke, Kurt , Riaz, Irbaz Bin , Sartor, Oliver , Mitchell, Sandra A , Cheville, Andrea

Mayo Clinic

Journal of Clinical Oncology | June 13, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 12079-12079

10.1200/jco.2024.42.16_suppl.12079 Get It

12079 Background: Many troublesome symptoms experienced by men with prostate cancer are not specific to a particular disease state or treatment modality. As such, these issues' scope is neither fully appreciated nor characterized in the reporting of clinical trial data. A modern accounting of poorly controlled symptoms is needed to better inform survivorship and supportive care efforts. Methods: Data are drawn from the Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) study, a cluster-randomized stepped wedge trial examining the effectiveness of routine symptom assessment and management on patient-centered outcomes and healthcare utilization (NCT03892967). This is a population-level study supporting patients with cancer, who are cared for in medical oncology clinics across the Midwest United States. The trial utilizes an automated symptom monitoring system with EHR-enabled algorithms for symptom triage and intervention. The current analysis focuses on pre-intervention surveys. The cohort includes E2C2 participants with prostate cancer (as determined by the Mayo Clinic Cancer Registry) receiving curative or palliative-intent therapies, along with prostate cancer survivors who previously completed their treatment. The prevalence of SPPADE symptoms (sleep disturbance, pain, impaired physical function, anxiety, depression, fatigue [low energy]) was assessed using 0 to 10 numerical rating scales (NRS), with scores of 4-6 indicating moderate symptoms and 7-10 indicating severe symptoms. Results: A total of 1,388 men with prostate cancer completed a pre-intervention survey between March 2019 and January 2023. The median age at completion of first survey was 74 years. The cohort includes patients living in diverse settings, including urban (n=718, 52%), micropolitan (n=250, 18%), small town (n=218, 16%), and rural (n=200, 14%) environments. The proportion of patients experiencing moderate-to-severe symptoms (NRS score ≥4) was 47% for fatigue, 40% for impaired physical function, 32% for sleep disturbance, 27% for pain, 22% for anxiety, and 20% for depression/emotional distress. The three domains with the highest prevalence of severe symptoms (NRS score ≥7) were fatigue (17%), impaired physical function (12%), and sleep disturbance (10%). Conclusions: Proactive symptom monitoring identifies a high overall burden of moderate-to-severe symptoms, particularly fatigue and impaired physical function, among prostate cancer patients and survivors. Collaborative care approaches and symptom control trials are needed to mitigate and manage these burdensome symptoms. Clinical trial information: NCT03892967 . [Table: see text]
Opioids and the Gastrointestinal Tract: The Role of Peripherally Active µ-Opioid Receptor Antagonists in Modulating Intestinal Permeability
Lacy, Brian E. , Cangemi, David J.

Mayo Clinic

American Journal of Gastroenterology | June 13, 2024 | Volume: 119 | Issue: 10 | Pages: 1970-1978

10.14309/ajg.0000000000002887 | PMID 38870087 Get It

Opioid receptors are found throughout the gastrointestinal tract, including the large intestine. Many patients treated with opioids experience opioid-induced constipation (OIC). Laxatives are not effective in most patients, and in those who do initially respond, the efficacy of laxatives generally diminishes over time. In addition, OIC does not spontaneously resolve for most patients. However, complications of opioids extend far beyond simply slowing gastrointestinal transit. Opioid use can affect intestinal permeability through a variety of mechanisms. Toll-like receptors are a crucial component of innate immunity and are tightly regulated within the gut epithelium. Pathologic µ-opioid receptor (MOR) and toll-like receptor signaling, resulting from chronic opioid exposure, disrupts intestinal permeability leading to potentially harmful bacterial translocation, elevated levels of bacterial toxins, immune activation, and increased cytokine production. Peripherally active MOR antagonists, including methylnaltrexone, are effective at treating OIC. Benefits extend beyond simply blocking the MOR; these agents also act to ameliorate opioid-induced disrupted intestinal permeability. In this review, we briefly describe the physiology of the gastrointestinal epithelial border and discuss the impact of opioids on gastrointestinal function. Finally, we consider the use of peripherally active MOR antagonists to treat disrupted intestinal permeability resulting from opioid use and discuss the potential for improved morbidity and mortality in patients treated with methylnaltrexone for opioid-induced bowel disorders.
Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).
Chen, Li , Das, Biswajit , Ge, Liner , Druta, Mihaela , Keohan, Mary Louise , Agulnik, Mark , D’Amato, Gina Z. , Seetharam, ­Mahesh , Pelosof, Lorraine, Tine, Brian Andrew Van, Weiss, Mia C. , Lacuna, Kristine Peregrino , Ingham, Matthew , Lee, Shing Mirn , Conley, Anthony P. , Burgess, Melissa , Chalmers, Anna Weinberg , Powers, Benjamin , Siontis, Brittany L. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | June 13, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11526-11526

10.1200/jco.2024.42.16_suppl.11526 Get It

11526 Background: There are no FDA-approved treatments for advanced cCS. Chemotherapy provides limited benefit. IDH1/2 mutations (m) occur in 50% of cCS. Both IDHm and wild-type cCS harbor epigenetic dysregulation. In preclinical models, HDAC + DNMT inhibition (i) suppressed growth by inducing apoptosis, reversing the hypermethylated state, and upregulating expression of interferon (IFN) response genes including PDL1(1). This prompted a phase 2 study of HDACi + DNMTi in cCS, which failed to meet the 1° endpoint of ORR. The majority of pts had a best response of stable disease, with a trend towards improved mPFS in IDHm (2). Here we report correlative analysis of NCI 10330. Methods: NCI 10330 is a single-arm, multicenter, phase 2 study of belinostat with SGI-110 or ASTX727 in advanced cCS. All pts were required to have pre- and on-treatment (tx) biopsies (Cycle 2, Day 3-5). Tissue was evaluated with whole exome sequencing (WES) and RNA sequencing (RNAseq). From RNAseq, Tumor Inflammation Signature Scores (TISS) and Tumor Microenvironment functional Gene Set Enrichment Analysis scores (TME GSEA) were calculated as the mean of the log2 normalized counts of 18 signature genes (Danaher et al. J Imm Can 2018) and pre-defined gene sets (3), respectively. Wilcoxon rank sum test was used to analyze TME GSEA between pre- and on-tx samples. Differential expression was significant if |FC| > 1.33, adjusted P <0.01. Results: 19 pts were treated; all received paired biopsies. WES was adequate in 7/19 (37%) pts, with IDHm identified in 3/7 (43%) pts. All pts were MSI-stable, TMB: 1.01-3.57 mut/Mb. RNAseq was adequate in 7/19 (37%) pts at pre-tx and 5/19 (26%) pts at on-tx. TISS ranges trended higher for pre-tx (8.77-10.14) vs on-tx (7.36-9.51) samples. TME GSEA identified significantly enriched tumor immune infiltration (p < 0.05) in pre- vs on-tx samples. Differential analysis identified several gene sets related to inflammation overexpressed in pre-tx samples only, including IFN response. On-tx samples were enriched in myogenesis and coagulation gene sets. Conclusions: This is the first study to describe transcriptomic changes following epigenetic tx in cCS. Contradictory to our preclinical data, HDACi + DNTMi resulted in low expression of inflammation. Prior studies reported that the immune infiltrate of CS at progression is immunosuppressive; higher immune infiltrate is correlated with worse outcomes (4). Loss of inflammation may have implications for disease stability experienced by most pts on NCI 10330. Further analyses are planned to correlate TME (pro- vs anti-inflammatory infiltrates) and outcomes. Analyses are limited by small sample size, highlighting the challenges in collecting adequate CS specimens. 1. Sheikh, Schwartz et al. Mol Cancer Ther 2021. 2. Lacuna et al. ASCO 2023: #11531. 3. Bagaev et al. Can Cell 2021. 4. Richert et al. J Bone Onc 2020. Clinical trial information: NCT04340843 .